STXBP1 disorder is a rare genetic condition that affects how brain cells communicate, causing seizures, developmental delays, and intellectual disability that typically appear in the first weeks or months of life. It occurs in roughly 3.3 to 3.8 out of every 100,000 births, making it one of the more common single-gene causes of severe epilepsy. The condition results from a mutation in the STXBP1 gene, and the vast majority of cases arise spontaneously rather than being inherited from a parent.
How the Gene Affects the Brain
The STXBP1 gene provides instructions for making a protein called Munc18-1, which plays a central role in how nerve cells release chemical signals to one another. When one neuron needs to send a message to the next, tiny packages of signaling chemicals (neurotransmitters) must fuse with the cell membrane and release their contents into the gap between cells. Munc18-1 helps orchestrate that fusion process, working alongside a group of proteins that physically pull the membrane of the package and the cell membrane together.
When Munc18-1 doesn’t work properly, the release of multiple neurotransmitters is disrupted, including dopamine, glutamate, and GABA. Because GABA is the brain’s primary calming signal and glutamate is its primary excitatory signal, an imbalance in their release can make the brain either too excitable or too sluggish in different circuits. This explains why the disorder produces such a wide range of neurological problems, from seizures to movement difficulties to cognitive impairment.
Genetics and Inheritance
Nearly all reported cases of STXBP1 disorder are caused by de novo mutations, meaning the genetic change occurs for the first time in the affected child rather than being passed down from either parent. In a large review of 162 patients, 140 had confirmed de novo mutations. The mutations are spread across multiple regions of the gene. Only one working copy of the gene is needed for normal brain function, so a single mutated copy is enough to cause symptoms.
Because the mutations are almost always new and spontaneous, parents of an affected child generally have a very low chance of having another child with the same condition. Genetic counseling can clarify the specific risk based on the family’s test results.
Seizures and Epilepsy
Epilepsy is a defining feature of the disorder for most children. The median age of seizure onset is six weeks, though seizures can begin as early as the first day of life or as late as age 13. Infantile spasms, which look like brief clusters of sudden stiffening or jerking, are among the most common early seizure types. Children may also experience tonic-clonic seizures (full-body stiffening and shaking), myoclonic jerks (quick muscle twitches), atonic seizures (sudden loss of muscle tone causing a drop), absence seizures (brief staring spells), and focal seizures that start in one part of the brain.
EEG patterns vary but often show distinctive abnormalities such as burst suppression (alternating bursts of electrical activity and flat periods) or hypsarrhythmia (a chaotic pattern associated with infantile spasms). Seizures can be difficult to control. In adult follow-up studies, 80% of patients had treatment-resistant epilepsy, even though 38% experienced long stretches of seizure freedom along the way. Infantile spasms, in particular, can persist or recur into adulthood.
Developmental and Cognitive Effects
Developmental delay is present in virtually all affected individuals and is usually apparent early. Children typically reach motor milestones late. In documented cases, independent walking may not happen until age four or later, and first words may not emerge until around age two. The severity of intellectual disability varies, but the majority of individuals are significantly affected. Among adults studied, 87% had severe or profound intellectual disability, and 71% were nonverbal.
Periods of developmental regression, where a child loses skills they previously had, occur in about 58% of individuals. These regressions don’t always line up with seizure activity, suggesting they can be a separate feature of the disorder rather than purely a consequence of uncontrolled epilepsy. Autism spectrum features are reported in roughly 42% of affected individuals, and 62% have significant behavioral challenges.
Movement Disorders
Beyond seizures, STXBP1 disorder frequently causes a range of movement problems. These can appear with or without epilepsy. The most common movement issues include:
- Tremor: present in over half of adults, usually an action or intention tremor that worsens when reaching for objects. Head tremor may appear in infancy.
- Ataxia: unsteady, uncoordinated movement affecting walking and balance. A broad-based gait is common.
- Low muscle tone (hypotonia): especially in the trunk, often noticeable from birth.
- Dystonia: involuntary muscle contractions causing unusual postures, particularly in the fingers and limbs.
- Stereotypies and dyskinesia: repetitive movements and involuntary writhing or jerking.
Walking ability in adulthood is variable. About half of adults walk independently, while 39% are fully wheelchair-dependent. Among those who can walk, gait abnormalities are universal, including postural irregularities and externally rotated feet.
How It Is Diagnosed
STXBP1 disorder is diagnosed through genetic testing. Because the symptoms overlap with many other causes of early-onset epilepsy and developmental delay, most families reach a diagnosis after broad genetic testing such as whole exome sequencing or an epilepsy gene panel. These tests scan hundreds or thousands of genes simultaneously and can identify the specific mutation in STXBP1. Earlier in the diagnostic journey, EEG findings like burst suppression in a newborn with seizures may prompt a clinician to order genetic testing, but the EEG pattern alone isn’t enough for a definitive diagnosis.
Treatment and Daily Management
There is no cure for STXBP1 disorder at this time, and treatment focuses on managing symptoms. Seizure control is a primary goal, typically involving anti-seizure medications. Because the seizures are often resistant to treatment, many children and adults cycle through multiple medications or combinations to find the most effective approach. The specific medication strategy depends on the seizure types present.
Supportive therapies play a large role in daily life. Physical therapy addresses low muscle tone, movement disorders, and mobility. Occupational therapy helps with fine motor skills and daily tasks like feeding and dressing. Speech therapy targets communication, which is a major area of need given that most affected individuals have limited or no verbal language. Some families use augmentative communication devices or sign language. Behavioral support may also be part of the care plan for children with autism spectrum features or challenging behaviors.
Long-Term Outlook
STXBP1 disorder is a lifelong condition. Most individuals require full-time caregiving support into adulthood for daily activities like eating, bathing, and dressing. Cognitive impairment remains significant, and seizures often persist, though their frequency and severity can change over the years. Movement disorders tend to involve multiple systems and may become more prominent with age.
A gene therapy clinical trial (CAP-002) is currently underway for children between 18 months and 8 years of age with STXBP1 encephalopathy. This Phase 1/2a trial is testing a single intravenous dose designed to deliver a working copy of the gene. It is the first human trial of gene therapy for this condition, and while it represents a meaningful step, results are not yet available. Families interested in emerging treatment options can search for active trials on ClinicalTrials.gov using “STXBP1” as a keyword.